Inflammatory mediators from AT, such as leptin, adiponectin, TNF-α, and IL-6, offer promising biomarkers for risk stratification, disease monitoring, and precision therapies targeting adipokine pathways or host modulation. Here, IL6 is linked to ataxia telangiectasia.